<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163084</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2010-01737</org_study_id>
    <secondary_id>NCI-2010-01737</secondary_id>
    <secondary_id>CDR0000670590</secondary_id>
    <secondary_id>2009-0473</secondary_id>
    <secondary_id>8384</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <nct_id>NCT01163084</nct_id>
  </id_info>
  <brief_title>Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer</brief_title>
  <official_title>A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I/II trial studies giving leuprolide acetate or goserelin acetate
      together with or without vismodegib followed by surgery to see how well they work in treating
      patients with prostate cancer that has spread from where it started to nearby tissue or lymph
      nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as
      leuprolide acetate or goserelin acetate, may lessen the amount of androgens made by the body.
      Vismodegib may slow the growth of tumor cells. Giving antihormone therapy together with
      vismodegib may be an effective treatment for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the difference in less than or equal to 5% tumor involvement between patients
      between the two arms.

      SECONDARY OBJECTIVES:

      I. To assess differences in hedgehog signaling, androgen signaling, markers linked to high
      grade prostate cancer (PCa) progression, proliferation, apoptosis, and the expression of
      androgen producing enzymes in the tumor microenvironment between the two arms.

      II. To assess safety of preoperative GDC-0449 (vismodegib) in combination with luteinizing
      hormone-releasing hormone (LHRH).

      III. To assess the difference in proportion of patients with negative disease surgical
      margins between the two arms.

      IV. To collect and archive tissue from the primary tumor, bone marrow and blood (serum,
      plasma), bone marrow aspirate for future study.

      V. To assess difference in relapse rate (biochemical, objective) and time to progression.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I (androgen-ablation therapy and vismodegib): Patients receive LHRH analogue comprising
      leuprolide acetate intramuscularly (IM) or goserelin acetate subcutaneously (SC) on day 1 and
      vismodegib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up
      to 16 weeks in the absence of disease progression or unacceptable toxicity.

      ARM II (androgen-ablation therapy): Patients receive LHRH analogue comprising leuprolide
      acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks
      in the absence of disease progression or unacceptable toxicity.

      After completion of study therapy, patients undergo radical prostatectomy.

      After completion of study therapy, patients are followed up every 6 months for up to 8 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">July 9, 2010</start_date>
  <completion_date type="Actual">June 1, 2012</completion_date>
  <primary_completion_date type="Actual">June 1, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with =&lt; 5% tumor involvement</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Each patient's pathologic staging will be assessed from the samples collected from prostatectomy. Will be descriptively summarized. Two-sided Chi-Square test will be used to provide the test of significance between the 2 groups of LHRHa versus LHRHa plus vismodegib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients expressing differences in hedgehog, androgen signaling and related genes markers</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in relapse rates by PSA levels (biochemical)</measure>
    <time_frame>Baseline to up to 8 years</time_frame>
    <description>Will be descriptively summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in relapse rates by bone scan/computed tomography scan (objective)</measure>
    <time_frame>Baseline to up to 8 years</time_frame>
    <description>Will be descriptively summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA (biochemical) progression, defined as PSA recurrence</measure>
    <time_frame>From the date of surgery and elevated post operative PSA concentration, assessed up to 8 years</time_frame>
    <description>Will be descriptively summarized. PSA recurrence is defined as two (2) serial measureable rises in PSA concentration above the undetectable level with the standard assay (&gt; 0.1 ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA (clinical) progression, defined as a serial rise in PSA concentration in the presence of castrate serum testosterone concentration or radiographic evidence of progression</measure>
    <time_frame>From the date of surgery and elevated post operative PSA concentration, assessed up to 8 years</time_frame>
    <description>Will be descriptively summarized. PSA recurrence is defined as two (2) serial measureable rises in PSA concentration above the undetectable level with the standard assay (&gt; 0.1 ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the rate of positive surgical margins between the two groups</measure>
    <time_frame>Baseline to up to 8 years</time_frame>
    <description>Will be descriptively summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with PSA =&lt; 0.2 ng/mL</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>Will be descriptively summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage IIA Prostate Cancer AJCC v7</condition>
  <condition>Stage IIB Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (leuprolide acetate, goserelin acetate, vismodegib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (leuprolide acetate, goserelin acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (leuprolide acetate, goserelin acetate, vismodegib)</arm_group_label>
    <arm_group_label>Arm II (leuprolide acetate, goserelin acetate)</arm_group_label>
    <other_name>ZDX</other_name>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (leuprolide acetate, goserelin acetate, vismodegib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (leuprolide acetate, goserelin acetate, vismodegib)</arm_group_label>
    <arm_group_label>Arm II (leuprolide acetate, goserelin acetate)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (leuprolide acetate, goserelin acetate, vismodegib)</arm_group_label>
    <other_name>Erivedge</other_name>
    <other_name>GDC-0449</other_name>
    <other_name>Hedgehog Antagonist GDC-0449</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologic proof of prostatic adenocarcinoma via a minimum of 6
             core biopsy samples

          -  Clinical stage T1c or T2 with high-grade disease (Gleason's 8-10) on initial biopsy
             and prostate specific antigen (PSA) &gt; 10 ng/ml, or clinical stage T2b-T2c with
             Gleason's grade &gt;= 7

          -  No evidence of metastatic disease as determined by imaging

          -  Initial therapy with antiandrogen treatment is allowed but must be within 4 weeks
             prior to study enrollment

          -  Appropriate surgical candidate for radical prostatectomy and an Eastern Cooperative
             Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Absence of major co-morbidity as determined by the treating physician

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;=100,000/mcL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =&lt;
             2.5 X institutional upper limit of normal

          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 50
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Patients must have prothrombin time (PT), partial thromboplastin time (PTT) and
             fibrinogen levels within institutional normal limits and no history of substantial
             non-iatrogenic bleeding diathesis

          -  Men and their female partners must agree to use two forms of contraception (i.e.,
             barrier contraception and one other method of contraception) during study treatment
             and for at least 12 months post-treatment

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Histologic variants in the primary tumor (histologic variants other than
             adenocarcinoma)

          -  Patients who have had chemotherapy or radiotherapy for prostate cancer prior to
             entering the study

          -  Patients who have received prior treatment with GDC-0449

          -  Patients may not be receiving any other investigational agents

          -  Patients receiving previous androgen ablation or current androgen ablation of greater
             than 4 week's duration

          -  Patients who are not appropriate surgical candidates for radical prostatectomy based
             on the evaluation of co-existent medical diseases and competing causes of death (such
             as but not limited to, unstable angina, myocardial infarction within the previous 6
             months, or use of ongoing maintenance therapy for life-threatening ventricular
             arrhythmia, uncontrolled hypertension)

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to GDC-0449 or LHRH analogues

          -  Patients taking medications with narrow therapeutic indices that are metabolized by
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®) are ineligible

          -  Patients with malabsorption syndrome or other condition that would interfere with
             intestinal absorption; patients must be able to swallow capsules

          -  Patients with clinically important (in the opinion of the treating physician) history
             of liver disease, including viral or other hepatitis or cirrhosis are ineligible

          -  Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia
             defined as less than the lower limit of normal for the institution, despite adequate
             electrolyte supplementation are excluded from this study

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Patients with prior malignancy if there is an increased chance (&gt;= 30%) of relapse in
             the following five years (in the opinion of the treating physician)

          -  Patients who have received systemic treatment for cancer within the last 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Logothetis</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

